SUNRISE, FL -- (Marketwire) -- 12/03/12 -- Bioheart Inc. (BHRT.QB) previously announced that its cGMP facility would be utilized by Stemlogix to help promote regenerative medicine for the veterinary market. Stemlogix has just announced the first ever combination regenerative medicine treatment on a six-year-old Quarter Reined Cow horse that suffered a significant injury to its distal straight sesamoidean ligament.

"The facilities at Bioheart Inc. are top notch and we are excited to move these new therapies for animals forward using state-of-the-art cGMP laboratories. We are fortunate to have the support and expertise of the Bioheart team," said Jason Griffeth, Chief Operating Officer of Stemlogix, LLC.

To provide him with this groundbreaking treatment, two small fat samples were taken from the base of his tail via a minimally invasive lipoaspirate procedure. Fat tissue is the richest source of stem cells for both human patients and animal patients. One of the tissue samples was processed on-site to provide a same-day, point-of-care stem cell treatment while the other tissue sample was sent to the cGMP laboratory where the mesenchymal stem cells were isolated and expanded for three weeks. A portion of his stem cells were also cryopreserved for future use.

Bioheart's president and CEO, Mike Tomas said, "Bioheart is focused on commercializing cell therapies for cardiac patients and has many years' experience with a variety of different cell types. This partnership allows us to utilize our existing laboratories and expertise to bring these products to the veterinary market."

About Bioheart, Inc.

Bioheart is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Bioheart's goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.

Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit www.bioheartinc.com, or visit us on Facebook: Bioheart and Twitter @BioheartInc.

About Stemlogix, LLC

Stemlogix high quality stem cell therapy and other regenerative medicine therapies are impacting the lives of cats, dogs and horses around the U.S. and in other countries. The company has developed a scientifically validated method for harvesting stem cells from both fat tissue and bone marrow for therapeutic use. The Stemlogix stem cell isolation processes provide for consistent cellular products that are compliant with current regulatory guidelines. Stemlogix has a highly experienced management team with over 20 years combined experience in developing multiple stem cell therapeutics for both human and animal use. In all of its products and services, Stemlogix aims to provide the best cutting-edge regenerative medical solutions, and seeks to provide companion animals and horses with renewed health and vitality. The company has partnered with Butler Schein Animal Health™, the leading companion animal health distribution company in the U.S., who are demonstrating the ease and effectiveness of the Stemlogix regenerative medicine treatments to veterinarians nationwide. To learn more about Stemlogix, LLC and its wide range of innovative regenerative medicine products please visit www.stemlogix.com, send an email to info@stemlogix.com or contact your local Butler Schein Animal Health™ representative.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2011, and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2012.

Add to Digg Bookmark with del.icio.us Add to Newsvine